Welcome to
Chiesi group
At Chiesi, upholding the highest ethical standards is a daily priority across all aspects of our business. We operate with integrity, fairness, responsibility, transparency, and in compliance with the law, reflecting our mission: "To combine a commitment to results with integrity, while being socially and environmentally responsible."
This commitment is reinforced by our value: "We interact with integrity and trust."
Our Group Human Rights Policy, published in 2023, reaffirms our commitment to prohibiting child labor, forced labor, harassment, abuse, and discrimination. It also emphasizes freedom of association, health and safety, psychological safety, and work-life balance.
To ensure this, we have adopted a Code of Conduct, implemented across all subsidiaries. Our Anti-Bribery Policy (last updated in 2023) provides clear guidance on preventing bribery and corruption, ensuring compliance throughout the Group.
Human rights are also a key focus of Chiesi's Code of Interdependence, our supplier code of conduct. We promote decent work through fair conditions, child labor prevention, workers’ rights, and social dialogue.
In Italy, Chiesi Farmaceutici S.p.A. has implemented an Organizational, Management, and Control Model (Model 231) to outline our ethical responsibilities and prevent unlawful behavior.
Our whistleblowing platform, SpeakUp&BeHeard, enables anyone to report misconduct or breaches of Chiesi’s Code of Conduct or legal violations, including issues related to diversity, health and safety, human rights, bribery, data protection, and more.
We are committed to transparency by openly reporting both our positive and negative impacts, providing stakeholders with data to make informed decisions. Our non-financial reporting framework integrates regulatory standards, industry best practices, and internal objectives to ensure reliability and accountability.
Chiesi ensures transparency in clinical trials by publicly disclosing study protocols and results in registries like ClinicalTrials.gov and the EU Clinical Trials Register. We comply with privacy and data sharing requirements, ensuring information is available for phase 2-4 trials and certain non-interventional studies within 12 months of completion.
Based on the rules set out in the EFPIA Code of Practice on transparency of transfer of value between pharmaceutical companies, Healthcare Professionals, Healthcare Organizations and Patient Associations, which are also reflected in the Farmindustria Code of Conduct, our company has committed itself to publishing data on these transfers of value annually at European level, starting in 2015 (first publication on June 30th, 2016).
Below you will find data on the transfer of values concerning Chiesi Farmaceutici S.p.A. and the Chiesi Group Affiliates.
Information on the publication criteria can be found in the Methodological Note.
For information about the transfer of value regulations please consult the following website: www.farmindustria.it (from the Home Page go to the Deontological Code section) or contact the Chiesi Transparency Contact Point at the following email address: dpoit@chiesi.com.
For requests made by the media, please contact Mediarelations@chiesi.com
REPORT
This is the content of Tab 2.
